Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

Next-generation muscle-directed gene therapy by in silico vector design.

Sarcar S, Tulalamba W, Rincon MY, Tipanee J, Pham HQ, Evens H, Boon D, Samara-Kuko E, Keyaerts M, Loperfido M, Berardi E, Jarmin S, In't Veld P, Dickson G, Lahoutte T, Sampaolesi M, De Bleser P, VandenDriessche T, Chuah MK.

Nat Commun. 2019 Jan 30;10(1):492. doi: 10.1038/s41467-018-08283-7.

2.

Getting Into the Rhythm With CRISPR.

VandenDriessche T, Chuah MK.

Circ Res. 2018 Sep 28;123(8):928-930. doi: 10.1161/CIRCRESAHA.118.313876. No abstract available.

PMID:
30355043
3.

Gene and Cell Therapy: Tearing Down Walls.

VandenDriessche T.

Hum Gene Ther. 2018 Oct;29(10):1071-1073. doi: 10.1089/hum.2018.29074.tva. No abstract available.

PMID:
30280978
4.

2BIC: taking your adventuring gear to organise pop-up health information literacy sessions.

Vandendriessche T, Michels M, Stoop L, Vissenaekens N, Discart I.

Health Info Libr J. 2018 Sep;35(3):256-261. doi: 10.1111/hir.12220.

PMID:
30160383
5.

Accuracy of Tissue and Sonication Fluid Sampling for the Diagnosis of Fracture-Related Infection: A Systematic Review and Critical Appraisal.

Onsea J, Depypere M, Govaert G, Kuehl R, Vandendriessche T, Morgenstern M, McNally M, Trampuz A, Metsemakers WJ.

J Bone Jt Infect. 2018 Aug 10;3(4):173-181. doi: 10.7150/jbji.27840. eCollection 2018.

6.

Efficient CRISPR/Cas9-mediated editing of trinucleotide repeat expansion in myotonic dystrophy patient-derived iPS and myogenic cells.

Dastidar S, Ardui S, Singh K, Majumdar D, Nair N, Fu Y, Reyon D, Samara E, Gerli MFM, Klein AF, De Schrijver W, Tipanee J, Seneca S, Tulalamba W, Wang H, Chai YC, In't Veld P, Furling D, Tedesco FS, Vermeesch JR, Joung JK, Chuah MK, VandenDriessche T.

Nucleic Acids Res. 2018 Sep 19;46(16):8275-8298. doi: 10.1093/nar/gky548.

7.

Haemophilia gene therapy: From trailblazer to gamechanger.

Evens H, Chuah MK, VandenDriessche T.

Haemophilia. 2018 May;24 Suppl 6:50-59. doi: 10.1111/hae.13494. Review.

PMID:
29878653
8.

Autogenous transalveolar transplantation of maxillary canines: a systematic review and meta-analysis.

Grisar K, Chaabouni D, Romero LPG, Vandendriessche T, Politis C, Jacobs R.

Eur J Orthod. 2018 Nov 30;40(6):608-616. doi: 10.1093/ejo/cjy026.

9.

A Calsequestrin Cis-Regulatory Motif Coupled to a Cardiac Troponin T Promoter Improves Cardiac Adeno-Associated Virus Serotype 9 Transduction Specificity.

Chamberlain K, Riyad JM, Garnett T, Kohlbrenner E, Mookerjee A, Elmastour F, Benard L, Chen J, VandenDriessche T, Chuah MK, Marian AJ, Hajjar RJ, Gurha P, Weber T.

Hum Gene Ther. 2018 Aug;29(8):927-937. doi: 10.1089/hum.2017.188. Epub 2018 May 9.

PMID:
29641321
10.

Efficient In Vivo Liver-Directed Gene Editing Using CRISPR/Cas9.

Singh K, Evens H, Nair N, Rincón MY, Sarcar S, Samara-Kuko E, Chuah MK, VandenDriessche T.

Mol Ther. 2018 May 2;26(5):1241-1254. doi: 10.1016/j.ymthe.2018.02.023. Epub 2018 Mar 6.

11.

Hyperactive Factor IX Padua: A Game-Changer for Hemophilia Gene Therapy.

VandenDriessche T, Chuah MK.

Mol Ther. 2018 Jan 3;26(1):14-16. doi: 10.1016/j.ymthe.2017.12.007. Epub 2017 Dec 21. No abstract available.

12.

Assessing the landscape of percutaneous coronary chronic total occlusion treatment in Belgium and Luxembourg: the Belgian Working Group on Chronic Total Occlusions (BWGCTO) registry.

Maeremans J, Kayaert P, Bataille Y, Bennett J, Ungureanu C, Haine S, Vandendriessche T, Sonck J, Scott B, Coussement P, Dendooven D, Pereira B, Frambach P, Janssens L, Debruyne P, Van Mieghem C, Barbato E, Cornelis K, Stammen F, De Vroey F, Vercauteren S, Drieghe B, Aminian A, Debrauwere J, Carlier S, Coosemans M, Van Reet B, Vandergoten P, Dens JA; (On behalf of the BWGCTO Investigators).

Acta Cardiol. 2017 Nov 28:1-10. doi: 10.1080/00015385.2017.1408891. [Epub ahead of print]

PMID:
29183248
13.

Preclinical and clinical advances in transposon-based gene therapy.

Tipanee J, Chai YC, VandenDriessche T, Chuah MK.

Biosci Rep. 2017 Dec 5;37(6). pii: BSR20160614. doi: 10.1042/BSR20160614. Print 2017 Dec 22. Review.

14.

Transposons: Moving Forward from Preclinical Studies to Clinical Trials.

Tipanee J, VandenDriessche T, Chuah MK.

Hum Gene Ther. 2017 Nov;28(11):1087-1104. doi: 10.1089/hum.2017.128. Epub 2017 Aug 22. Review.

PMID:
28920716
15.

Comparison of radial access versus femoral access with the use of a vascular closure device for the prevention of vascular complications and mortality after percutaneous coronary intervention.

Téblick A, Vanderbruggen W, Vandendriessche T, Bosmans J, Haine SEF, Miljoen H, Segers V, Wouters K, Vrints C, Claeys MJ.

Acta Cardiol. 2018 Jun;73(3):241-247. doi: 10.1080/00015385.2017.1363947. Epub 2017 Aug 29.

PMID:
28851255
16.

A higher volume of fibrotic tissue on virtual histology prior to coronary stent implantation predisposes to more pronounced neointima proliferation.

Haine S, Wouters K, Miljoen H, Vandendriessche T, Claeys M, Bosmans J, Vrints C.

Acta Cardiol. 2018 Apr;73(2):171-178. doi: 10.1080/00015385.2017.1351258. Epub 2017 Aug 11.

PMID:
28799447
17.

Hemophilia Gene Therapy: Ready for Prime Time?

VandenDriessche T, Chuah MK.

Hum Gene Ther. 2017 Nov;28(11):1013-1023. doi: 10.1089/hum.2017.116. Epub 2017 Aug 3. Review.

PMID:
28793786
18.

Failed Downregulation of Circulating MicroRNA-155 in the Early Phase after ST Elevation Myocardial Infarction Is Associated with Adverse Left Ventricular Remodeling.

Latet SC, Van Herck PL, Claeys MJ, Van Craenenbroeck AH, Haine SE, Vandendriessche TR, Van Hoof VO, Fransen E, De Winter BY, Van Craenenbroeck EM, Heidbuchel H, Vrints CJ, Hoymans VY.

Cardiology. 2017;138(2):91-96. doi: 10.1159/000477235. Epub 2017 Jun 16.

PMID:
28618412
19.

AAV9 delivered bispecific nanobody attenuates amyloid burden in the gelsolin amyloidosis mouse model.

Verhelle A, Nair N, Everaert I, Van Overbeke W, Supply L, Zwaenepoel O, Peleman C, Van Dorpe J, Lahoutte T, Devoogdt N, Derave W, Chuah MK, VandenDriessche T, Gettemans J.

Hum Mol Genet. 2017 Aug 1;26(15):3030. doi: 10.1093/hmg/ddx207. No abstract available.

PMID:
28605435
20.

A Novel Platform for Immune Tolerance Induction in Hemophilia A Mice.

Merlin S, Cannizzo ES, Borroni E, Bruscaggin V, Schinco P, Tulalamba W, Chuah MK, Arruda VR, VandenDriessche T, Prat M, Valente G, Follenzi A.

Mol Ther. 2017 Aug 2;25(8):1815-1830. doi: 10.1016/j.ymthe.2017.04.029. Epub 2017 May 26.

21.

AAV Capsid Engineering: Zooming in on the Target.

VandenDriessche T.

Hum Gene Ther. 2017 May;28(5):373-374. doi: 10.1089/hum.2017.29042.tva. No abstract available.

PMID:
28498776
22.

AAV9 delivered bispecific nanobody attenuates amyloid burden in the gelsolin amyloidosis mouse model.

Verhelle A, Nair N, Everaert I, Van Overbeke W, Supply L, Zwaenepoel O, Peleman C, Van Dorpe J, Lahoutte T, Devoogdt N, Derave W, Chuah MK, VandenDriessche T, Gettemans J.

Hum Mol Genet. 2017 Apr 1;26(7):1353-1364. doi: 10.1093/hmg/ddx056. Erratum in: Hum Mol Genet. 2017 Aug 1;26(15):3030.

PMID:
28334940
23.

Baboon envelope pseudotyped lentiviral vectors efficiently transduce human B cells and allow active factor IX B cell secretion in vivo in NOD/SCIDγc-/- mice.

Levy C, Fusil F, Amirache F, Costa C, Girard-Gagnepain A, Negre D, Bernadin O, Garaulet G, Rodriguez A, Nair N, Vandendriessche T, Chuah M, Cosset FL, Verhoeyen E.

J Thromb Haemost. 2016 Dec;14(12):2478-2492. doi: 10.1111/jth.13520. Epub 2016 Nov 8.

24.

CRISPR/Cas9 Flexes Its Muscles: In Vivo Somatic Gene Editing for Muscular Dystrophy.

VandenDriessche T, Chuah MK.

Mol Ther. 2016 Mar;24(3):414-6. doi: 10.1038/mt.2016.29. No abstract available.

25.

Adeno-Associated Virus Type 2 and Hepatocellular Carcinoma?

Berns KI, Byrne BJ, Flotte TR, Gao G, Hauswirth WW, Herzog RW, Muzyczka N, VandenDriessche T, Xiao X, Zolotukhin S, Srivastava A.

Hum Gene Ther. 2015 Dec;26(12):779-81. doi: 10.1089/hum.2015.29014.kib. No abstract available.

26.

piggyBac transposons expressing full-length human dystrophin enable genetic correction of dystrophic mesoangioblasts.

Loperfido M, Jarmin S, Dastidar S, Di Matteo M, Perini I, Moore M, Nair N, Samara-Kuko E, Athanasopoulos T, Tedesco FS, Dickson G, Sampaolesi M, VandenDriessche T, Chuah MK.

Nucleic Acids Res. 2016 Jan 29;44(2):744-60. doi: 10.1093/nar/gkv1464. Epub 2015 Dec 17.

27.

Corrigendum: Efficient derivation and inducible differentiation of expandable skeletal myogenic cells from human ES and patient-specific iPS cells.

Maffioletti SM, Gerli MF, Ragazzi M, Dastidar S, Benedetti S, Loperfido M, VandenDriessche T, Chuah MK, Tedesco FS.

Nat Protoc. 2015 Sep;10(9):1457. doi: 10.1038/nprot0915-1457d. Epub 2015 Aug 27. No abstract available.

PMID:
26313482
28.

Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation.

Rincon MY, VandenDriessche T, Chuah MK.

Cardiovasc Res. 2015 Oct 1;108(1):4-20. doi: 10.1093/cvr/cvv205. Epub 2015 Aug 3. Review.

29.

Pluripotent Stem Cells for Gene Therapy of Degenerative Muscle Diseases.

Loperfido M, Steele-Stallard HB, Tedesco FS, VandenDriessche T.

Curr Gene Ther. 2015;15(4):364-80. Review.

PMID:
26122099
30.

Efficient derivation and inducible differentiation of expandable skeletal myogenic cells from human ES and patient-specific iPS cells.

Maffioletti SM, Gerli MF, Ragazzi M, Dastidar S, Benedetti S, Loperfido M, VandenDriessche T, Chuah MK, Tedesco FS.

Nat Protoc. 2015 Jul;10(7):941-58. doi: 10.1038/nprot.2015.057. Epub 2015 Jun 4. Erratum in: Nat Protoc. 2015 Sep;10(9):1457.

PMID:
26042384
31.

Moving forward toward a cure for hemophilia B.

VandenDriessche T, Chuah MK.

Mol Ther. 2015 May;23(5):809-811. doi: 10.1038/mt.2015.56. No abstract available.

32.

Usefulness of early rule-in and rule-out biomarker protocols to estimate ischemia-induced myocardial injury in early chest pain presenters.

Vorlat A, Van Hoof VO, Hammami R, van Kerckhoven S, Van der Heijden CM, Coenen D, Bosmans JM, Haine S, Vandendriessche TR, Vrints CJ, Claeys MJ.

Am J Cardiol. 2015 Jun 15;115(12):1667-71. doi: 10.1016/j.amjcard.2015.03.012. Epub 2015 Mar 23.

PMID:
25929579
33.

Liver-directed lentiviral gene therapy in a dog model of hemophilia B.

Cantore A, Ranzani M, Bartholomae CC, Volpin M, Valle PD, Sanvito F, Sergi LS, Gallina P, Benedicenti F, Bellinger D, Raymer R, Merricks E, Bellintani F, Martin S, Doglioni C, D'Angelo A, VandenDriessche T, Chuah MK, Schmidt M, Nichols T, Montini E, Naldini L.

Sci Transl Med. 2015 Mar 4;7(277):277ra28. doi: 10.1126/scitranslmed.aaa1405.

34.

Adiponectin and ischemia-reperfusion injury in ST segment elevation myocardial infarction.

De Roeck L, Vandamme S, Everaert BR, Hoymans V, Haine S, Vandendriessche T, Bosmans J, Ronsyn MW, Miljoen H, Van Berendoncks A, De Meyer G, Vrints C, Claeys MJ.

Eur Heart J Acute Cardiovasc Care. 2016 Feb;5(1):71-6. doi: 10.1177/2048872615570770. Epub 2015 Feb 26.

PMID:
25722457
35.

Hitting the target without pulling the trigger.

VandenDriessche T, Chuah MK.

Mol Ther. 2015 Jan;23(1):4-6. doi: 10.1038/mt.2014.230. No abstract available.

36.

Genome-wide computational analysis reveals cardiomyocyte-specific transcriptional Cis-regulatory motifs that enable efficient cardiac gene therapy.

Rincon MY, Sarcar S, Danso-Abeam D, Keyaerts M, Matrai J, Samara-Kuko E, Acosta-Sanchez A, Athanasopoulos T, Dickson G, Lahoutte T, De Bleser P, VandenDriessche T, Chuah MK.

Mol Ther. 2015 Jan;23(1):43-52. doi: 10.1038/mt.2014.178. Epub 2014 Sep 8.

37.

Hyperactive piggyBac transposons for sustained and robust liver-targeted gene therapy.

Di Matteo M, Samara-Kuko E, Ward NJ, Waddington SN, McVey JH, Chuah MK, VandenDriessche T.

Mol Ther. 2014 Sep;22(9):1614-24. doi: 10.1038/mt.2014.131. Epub 2014 Jul 18. Erratum in: Mol Ther. 2015 Oct;23(10):1671. Mol Ther. 2014 Nov;22(11):2013. Waddingon, Simon N [corrected to Waddington, Simon N].

38.

Percutaneous mitral valve repair in high-risk patients: initial experience with the Mitraclip system in Belgium.

Vandendriessche T, Kotrc M, Tijskens M, Bartunek J, Delesie M, Paelinck BP, De Bock D, Penicka M, Stockman B, De Maeyer C, Vrints C, Vanderheyden M, Claeys MJ.

Acta Cardiol. 2014 Jun;69(3):265-70.

PMID:
25029871
39.

Liver-specific transcriptional modules identified by genome-wide in silico analysis enable efficient gene therapy in mice and non-human primates.

Chuah MK, Petrus I, De Bleser P, Le Guiner C, Gernoux G, Adjali O, Nair N, Willems J, Evens H, Rincon MY, Matrai J, Di Matteo M, Samara-Kuko E, Yan B, Acosta-Sanchez A, Meliani A, Cherel G, Blouin V, Christophe O, Moullier P, Mingozzi F, VandenDriessche T.

Mol Ther. 2014 Sep;22(9):1605-13. doi: 10.1038/mt.2014.114. Epub 2014 Jun 23.

40.

Cost-effectiveness of contemporary vascular closure devices for the prevention of vascular complications after percutaneous coronary interventions in an all-comers PCI population.

Kerré S, Kustermans L, Vandendriessche T, Bosmans J, Haine SE, Miljoen H, Vrints CJ, Beutels P, Wouters K, Claeys MJ.

EuroIntervention. 2014 Jun;10(2):191-7. doi: 10.4244/EIJV10I2A32.

41.

Computationally designed liver-specific transcriptional modules and hyperactive factor IX improve hepatic gene therapy.

Nair N, Rincon MY, Evens H, Sarcar S, Dastidar S, Samara-Kuko E, Ghandeharian O, Man Viecelli H, Thöny B, De Bleser P, VandenDriessche T, Chuah MK.

Blood. 2014 May 15;123(20):3195-9. doi: 10.1182/blood-2013-10-534032. Epub 2014 Mar 17. Erratum in: Blood. 2015 Mar 19;125(12):2007. Dosage error in article text.

42.

Treatment of phenylketonuria using minicircle-based naked-DNA gene transfer to murine liver.

Viecelli HM, Harbottle RP, Wong SP, Schlegel A, Chuah MK, VandenDriessche T, Harding CO, Thöny B.

Hepatology. 2014 Sep;60(3):1035-43. doi: 10.1002/hep.27104. Epub 2014 Jul 29.

43.

Nondestructive measurement of fruit and vegetable quality.

Nicolaï BM, Defraeye T, De Ketelaere B, Herremans E, Hertog ML, Saeys W, Torricelli A, Vandendriessche T, Verboven P.

Annu Rev Food Sci Technol. 2014;5:285-312. doi: 10.1146/annurev-food-030713-092410. Epub 2014 Jan 2.

PMID:
24387604
44.

Levels of circulating CD34+/KDR+ cells do not predict coronary in-stent restenosis.

Haine SE, Van Craenenbroeck EM, Hoymans VY, Miljoen HP, Vandendriessche TR, Claeys MJ, Frederix G, Conraads VM, Bosmans JM, Vrints CJ.

Can J Cardiol. 2014 Jan;30(1):102-8. doi: 10.1016/j.cjca.2013.10.012. Epub 2013 Oct 24.

PMID:
24365195
45.

Optimizing delivery and expression of designer nucleases for genome engineering.

Chuah MK, VandenDriessche T.

Hum Gene Ther Methods. 2013 Dec;24(6):329-32. doi: 10.1089/hgtb.2013.166.

PMID:
24328735
46.

Percutaneous occlusion of post-myocardial infarction ventricular septum rupture.

Risseeuw F, Diebels I, Vandendriessche T, De Wolf D, Rodrigus IE.

Neth Heart J. 2014 Feb;22(2):47-51. doi: 10.1007/s12471-013-0498-4.

47.

Targeting endothelial cells by gene therapy.

Vandendriessche T, Chuah MK.

Blood. 2013 Sep 19;122(12):1993-4. doi: 10.1182/blood-2013-08-518266.

48.

Vector decoys trick the immune response.

VandenDriessche T, Chuah MK.

Sci Transl Med. 2013 Jul 17;5(194):194fs28. doi: 10.1126/scitranslmed.3006633.

PMID:
23863831
49.

Gene therapy for hemophilia.

Chuah MK, Evens H, VandenDriessche T.

J Thromb Haemost. 2013 Jun;11 Suppl 1:99-110. doi: 10.1111/jth.12215. Review.

50.

Glioblastoma: bridging the gap with gene therapy.

VandenDriessche T, Chuah MK.

Lancet Oncol. 2013 Aug;14(9):789-90. doi: 10.1016/S1470-2045(13)70342-5. Epub 2013 Jul 12. No abstract available.

PMID:
23850492

Supplemental Content

Loading ...
Support Center